LEXX

Contracts signed for Animal Study #2: GLP-1-A26-2Amycretin and retatrutide to be tested for compatibility with DehydraTECH KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO") to execute and report on its 2026 Animal Study #2 (GLP-1-A26-2) that will evaluate a number of formulation enhancements with two next-generation glucagon-like peptide-1 ("GLP-1") drugs in animals (the "Study") to explore the potential for improved DehydraTECH performance as well as potentially stake new intellectual property

600,000 New Wegovy® Pill Prescriptions Written in First Two Months KELOWNA, BC / ACCESS Newswire / April 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update of additional recent developments in the fast-moving glucagon-like peptide-1 ("GLP-1") oral (or "pill") market.The GLP-1 oral pill sector is growing much faster in 2026 than expected, and faster than the pre-existing GLP-1 injectable sector. The industry's first-ever GLP-1 pill for weight loss, Wegovy®, was approved by the US Food and Drug Administration ("FDA") on December 22, 2025 and launched in the US in January 2026. Prior to that, Rybel

Contracts signed for Animal Study GLP-1-A26-1KELOWNA, BC / ACCESS Newswire / April 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO") to execute and report on its 2026 animal Study #1 (GLP-1-A26-1) that will evaluate a number of formulation enhancements using both DehydraTECH-semaglutide ("DHT-sema") glucagon-like peptide-1 ("GLP-1") compositions and DehydraTECH-CBD ("DHT-CBD") compositions to explore the potential for additional improved performance as well as stake new intellectual property ("IP") claims (the "Study").Contracts wit

10-Q - Lexaria Bioscience Corp. (0001348362) (Filer)

The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effectsKELOWNA, BC / ACCESS Newswire / April 7, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to recognize that the US Food and Drug Administration ("FDA") has approved Eli Lilly and Company's® Foundayo™ glucagon-like peptide-1 ("GLP-1") agonist (orforglipron) oral tablet for adult use in controlling obesity and weight-related medical conditions."This latest approval from the FDA expands choices for Americans searching for the right weight control drug that best suits their needs," said Rich

Contracts signed for Human Pilot Study #7 (GLP-1-H26-7)KELOWNA, BC / ACCESS Newswire / April 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the engagement of the contract research organization ("CRO") to execute and report on its Human Pilot Study #7 (GLP-1-H26-7) that will evaluate 2 oral DehydraTECH-semaglutide ("DHT-sema") compositions against commercially available Wegovy® tablets (the "Study").Contracts with the CRO have been signed and submissions are currently being prepared to obtain the required ethics approval from an independent review board.Study design is virtually complete and

Lexaria receives 5 new patents including 2 for diabetes treatment utilizing GLP-1 drugsKELOWNA, BC / ACCESS Newswire / March 26, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this update on additional new intellectual property ("IP") granted to the Company as a result of its ongoing research and development ("R&D") programs. This new IP is recognized with the awarding of 5 new patents as detailed below."Lexaria is very proud of its internal team for their ingenuity and dedication to pushing scientific boundaries and also to having these achievements recognized by patent offices around the world

"The window to shape the oral GLP-1 market is open now...."Early-stage discussions with several multinational pharmaceutical companies currently underwayKELOWNA, BC / ACCESS Newswire / March 24, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms provides this update of developments within the glucagon-like peptide-1 ("GLP-1") market.Lexaria has been listening and responding to the concerns of those using GLP-1 drugs, who overwhelmingly indicate their preference for oral versus injected delivery and who are desperately seeking safer options whose side effects do not make them feel sick. This has driven Lexaria's mission t

4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

Exciting new human and animal studies designed to enhance business opportunitiesKELOWNA, BC / ACCESS Newswire / March 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the beginning of its 2026 research and development program (the "2026 R&D Program") designed to broaden pharmaceutical, intellectual property ("IP"), and business development opportunities through new and improved formulations.Information on 3 new studies from the 2026 R&D Program which are representative of the Company's primary areas of focus during at least the first three quarters of the calendar year, is being released today, however the

8-K - Lexaria Bioscience Corp. (0001348362) (Filer)

Company Further Examining the Pursuit of the World's First Oral Liraglutide ProductKELOWNA, BC / ACCESS Newswire / February 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce final results from Human Pilot Study #5 (GLP-1-H25-5) (the "Study"), which compared oral DehydraTECH-liraglutide ("DHT-LIR") capsules to injected Saxenda® branded liraglutide ("SAX-LIR")."We are extremely pleased with the results of Human Pilot Study #5," stated Richard Christopher, CEO of Lexaria. "In addition to achieving the Study's primary safety and tolerability endpoint, we also demonstrated that oral DehydraTECH-lira

8-K - Lexaria Bioscience Corp. (0001348362) (Filer)

S-8 - Lexaria Bioscience Corp. (0001348362) (Filer)

Lexaria now has 60 patents granted around much of the worldLexaria urges shareholders to vote at upcoming 2026 Annual MeetingKELOWNA, BC / ACCESS Newswire / January 22, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it has reached yet another important milestone in its strategy of building a strong and diverse intellectual property portfolio: the Company now has a total of 60 valid patents granted around most of the major potential markets around the world.Lexaria's previous update on patents was issued on October 9, 2025. Since then, we have diligently pursued legal recognition of our innovati

EFFECT - Lexaria Bioscience Corp. (0001348362) (Filer)

424B3 - Lexaria Bioscience Corp. (0001348362) (Filer)

10-Q - Lexaria Bioscience Corp. (0001348362) (Filer)

KELOWNA, BC / ACCESS Newswire / January 12, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this Annual Letter from its Chief Executive Officer ("CEO") Richard Christopher as a strategic update to all stakeholders.CEO Letter to StakeholdersDear Fellow Stakeholders,I'm truly honored to deliver Lexaria's Annual Letter from the CEO following my first full year in the position.I'm pleased to report that, in 2025, Lexaria made significant progress in further evidencing the potential to advance oral based drug delivery within the GLP-1 sector with the use of its proprietary DehydraTECHTM

KELOWNA, BC / ACCESS Newswire / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study" or the "Lexaria Study"), recently completed in Australia, focusing on 4 DehydraTECH™ ("DHT") study arms relative to the Rybelsus® control study arm."We are pleased to report additional data from our first Phase 1b clinical study," stated Richard Christopher, CEO of Lexaria. "It adds to a growing dataset which showcases the many potential benefits of our platform

S-3 - Lexaria Bioscience Corp. (0001348362) (Filer)

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus®DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus®Recent financings create runway for prospective new 2026 development opportunitiesKELOWNA, BC / ACCESS Newswire / December 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the " Study " or the " Lexaria Study "), recently completed in Australia, focusing on 4 DehydraTECH ® ( "DHT" ) study

8-K - Lexaria Bioscience Corp. (0001348362) (Filer)

KELOWNA, BC / ACCESS Newswire / December 16, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW)) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 2,661,600 shares of its common stock, par value $0.001 per share, at a purchase price of $1.315 per share. In addition, in a concurrent private placement, the Company issued unregistered warrants to purchase up to 2,661,600 shares of common stock. The warrants have an exercise price of $1.19 per share, are immediately exercisable and will expire five years from the date of the ef

424B5 - Lexaria Bioscience Corp. (0001348362) (Filer)